Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Notes Payables (2016 - 2025)

Guided Therapeutics' Notes Payables history spans 15 years, with the latest figure at $105000.0 for Q4 2025.

  • On a quarterly basis, Notes Payables fell 24.46% to $105000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $105000.0, a 24.46% decrease, with the full-year FY2025 number at $105000.0, down 24.46% from a year prior.
  • Notes Payables hit $105000.0 in Q4 2025 for Guided Therapeutics, down from $411000.0 in the prior quarter.
  • Over the last five years, Notes Payables for GTHP hit a ceiling of $421000.0 in Q2 2025 and a floor of $11000.0 in Q1 2021.
  • Historically, Notes Payables has averaged $109558.9 across 5 years, with a median of $59000.0 in 2023.
  • Biggest five-year swings in Notes Payables: plummeted 98.51% in 2021 and later soared 452.94% in 2023.
  • Tracing GTHP's Notes Payables over 5 years: stood at $48000.0 in 2021, then grew by 17.85% to $56569.0 in 2022, then rose by 4.3% to $59000.0 in 2023, then soared by 135.59% to $139000.0 in 2024, then dropped by 24.46% to $105000.0 in 2025.
  • Business Quant data shows Notes Payables for GTHP at $105000.0 in Q4 2025, $411000.0 in Q3 2025, and $421000.0 in Q2 2025.